Align Formate-dependent phosphoribosylglycinamide formyltransferase; 5'-phosphoribosylglycinamide transformylase 2; Formate-dependent GAR transformylase; GAR transformylase 2; GART 2; Non-folate glycinamide ribonucleotide transformylase; Phosphoribosylglycinamide formyltransferase 2; EC 2.1.2.- (characterized)
to candidate WP_198002428.1 MAEO_RS02770 formate-dependent phosphoribosylglycinamide formyltransferase
Query= SwissProt::P33221 (392 letters) >NCBI__GCF_000017185.1:WP_198002428.1 Length = 390 Score = 410 bits (1053), Expect = e-119 Identities = 213/391 (54%), Positives = 279/391 (71%), Gaps = 3/391 (0%) Query: 3 LLGTALRPAATRVMLLGSGELGKEVAIECQRLGVEVIAVDRYADAPAMHVAHRSHVINML 62 +LGT L T+++LLGSGELGKEV IE QRLG+E +AVD Y +APAM VAHRS+VI+M Sbjct: 1 MLGTPLFSNGTKILLLGSGELGKEVIIEAQRLGIECVAVDSYDNAPAMQVAHRSYVIDMK 60 Query: 63 DGDALRRVVELEKPHYIVPEIEAIATDMLIQLEEEGLNVVPCARATKLTMNREGIRRLAA 122 DGDAL+ ++E E P YI+PEIEAI TD+LI++EE G VVP A A K+TM+REGIRRLA+ Sbjct: 61 DGDALKAILEKEVPDYIIPEIEAINTDILIEMEEFGHQVVPTANAAKITMDREGIRRLAS 120 Query: 123 EELQLPTSTYRFADSESLFREAVADIGYPCIVKPVMSSSGKGQTFIRSA--EQLAQAWKY 180 E+L +PT+ Y FA+S ++AV IG PCIVKP+MSSSGKGQ+ ++S E + AW Y Sbjct: 121 EQLNIPTAKYEFAESLEELKKAVKKIGAPCIVKPIMSSSGKGQSTVKSEKDEDIEYAWNY 180 Query: 181 AQQGGRAGAGRVIVEGVVKFDFEITLLTVSAVDGVHFCAPVGHRQEDGDYRESWQPQQMS 240 AQ G R +VIVE + FD+EITLLT G +C P+GH Q+ GDY ESWQP MS Sbjct: 181 AQAGARGIGKKVIVEEFINFDYEITLLTARTAHGTVYCPPIGHIQDGGDYIESWQPHPMS 240 Query: 241 PLALERAQEIARKVVLALGGYGLFGVELFVCGDEVIFSEVSPRPHDTGMVTLISQDLSEF 300 +++AQE+A K+ LGG G+FGVELF+ GDEVIFSEVSPRPHDTGMVT+I+Q++SEF Sbjct: 241 EEMIKKAQEMANKITTVLGGNGIFGVELFIRGDEVIFSEVSPRPHDTGMVTMITQNMSEF 300 Query: 301 ALHVRAFLGLPVGGIRQYGPAASAVILPQLTSQNVTFDNVQNAVGADLQIRLFGKPEIDG 360 +H+R+ LGLPV I+ AS+VI ++ +D + ++R+FGKP Sbjct: 301 EIHLRSILGLPV-DIQLITAGASSVIKSKIHKYAPQYDISDAVKVPNTKLRIFGKPLAKV 359 Query: 361 SRRLGVALATAESVVDAIERAKHAAGQVKVQ 391 RR+GVALA+A +V +A + AK A V ++ Sbjct: 360 GRRMGVALASANTVEEARKNAKKCANGVIIR 390 Lambda K H 0.320 0.136 0.390 Gapped Lambda K H 0.267 0.0410 0.140 Matrix: BLOSUM62 Gap Penalties: Existence: 11, Extension: 1 Number of Sequences: 1 Number of Hits to DB: 392 Number of extensions: 12 Number of successful extensions: 3 Number of sequences better than 1.0e-02: 1 Number of HSP's gapped: 1 Number of HSP's successfully gapped: 1 Length of query: 392 Length of database: 390 Length adjustment: 31 Effective length of query: 361 Effective length of database: 359 Effective search space: 129599 Effective search space used: 129599 Neighboring words threshold: 11 Window for multiple hits: 40 X1: 16 ( 7.4 bits) X2: 38 (14.6 bits) X3: 64 (24.7 bits) S1: 41 (21.8 bits) S2: 50 (23.9 bits)
This GapMind analysis is from Apr 09 2024. The underlying query database was built on Sep 17 2021.
Each pathway is defined by a set of rules based on individual steps or genes. Candidates for each step are identified by using ublast (a fast alternative to protein BLAST) against a database of manually-curated proteins (most of which are experimentally characterized) or by using HMMer with enzyme models (usually from TIGRFam). Ublast hits may be split across two different proteins.
A candidate for a step is "high confidence" if either:
Otherwise, a candidate is "medium confidence" if either:
Other blast hits with at least 50% coverage are "low confidence."
Steps with no high- or medium-confidence candidates may be considered "gaps." For the typical bacterium that can make all 20 amino acids, there are 1-2 gaps in amino acid biosynthesis pathways. For diverse bacteria and archaea that can utilize a carbon source, there is a complete high-confidence catabolic pathway (including a transporter) just 38% of the time, and there is a complete medium-confidence pathway 63% of the time. Gaps may be due to:
GapMind relies on the predicted proteins in the genome and does not search the six-frame translation. In most cases, you can search the six-frame translation by clicking on links to Curated BLAST for each step definition (in the per-step page).
For more information, see:
If you notice any errors or omissions in the step descriptions, or any questionable results, please let us know
by Morgan Price, Arkin group, Lawrence Berkeley National Laboratory